혈우병 시장 : 유형별, 제품별, 요법별, 치료별, 지역별 규모, 점유율 및 성장 분석과 업계 예측(2026-2033년)

Hemophilia Market size was valued at USD 14.39 Billion in 2024 and is poised to grow from USD 15.34 Billion in 2025 to USD 25.58 Billion by 2033, growing at a CAGR of 6.6% during the forecast period (2026-2033).

The hemophilia treatment market is experiencing robust growth fueled by the recent approvals of gene therapies and a wealth of candidates in various stages of development. Enhanced awareness of hemophilia, coupled with government initiatives promoting early detection in newborns, further bolsters market expansion. The disorder predominantly affects males due to its sex-linked nature, contributing to its prevalence. Global surveys reveal a significant patient population, with many individuals diagnosed with types A, B, and unspecified hemophilia. This high prevalence is directly influencing the rising adoption of therapies, reinforcing the market's momentum. As stakeholders focus on innovative treatment solutions, the hemophilia landscape is poised for continued evolution and growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Hemophilia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Hemophilia Market Segments Analysis

Global Hemophilia Market is segmented by Type, Product, Therapy, Treatment and region. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, Hemophilia C and Others. Based on Product, the market is segmented into Plasma derived coagulation factor concentrates, Recombinant coagulation factor concentrates and Desmopressin and antifibrinolytic agents. Based on Therapy, the market is segmented into On-demand and Prophylaxis. Based on Treatment, the market is segmented into Replacement therapy, ITI therapy and Gene Therapy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Hemophilia Market

The hemophilia market is primarily driven by significant advancements in treatment approaches, including gene therapy, recombinant factor concentrates, and personalized medicine. These innovative therapies have transformed the management of hemophilia, leading to better patient outcomes and a marked improvement in overall quality of life for those affected by the disorder. As new treatment options continue to emerge, they not only enhance the efficacy of care but also offer patients more tailored solutions that meet their individual needs, ultimately contributing to the growth and evolution of the hemophilia market as healthcare providers seek to deliver optimal care.

Restraints in the Hemophilia Market

The hemophilia market faces significant constraints due to the high costs associated with treatments, especially innovative therapies like gene therapy. These financial burdens can create substantial obstacles for patients seeking effective care, often limiting their access to advanced therapeutic options. Healthcare systems may also experience strain as they navigate the expenses related to providing these sophisticated treatments. The economic challenges inherent in the hemophilia market can impede patient outcomes and hinder the overall progress of therapeutic advancements, emphasizing the need for more affordable solutions to enhance accessibility for individuals requiring care.

Market Trends of the Hemophilia Market

A prominent market trend in the hemophilia sector is the increasing integration of gene therapy, which is poised to transform treatment paradigms by targeting the root genetic issues of the disorder. This innovative approach aims to deliver functional genes that enable patients to synthesize essential clotting factors, significantly enhancing their quality of life. The rise of gene therapy is fueled by advancements in viral vector methodologies and a deeper comprehension of genetic manipulation. Numerous clinical trials have reported encouraging outcomes, indicating that gene therapy could offer enduring solutions and alleviate the ongoing need for conventional factor replacement therapies, thereby reshaping the treatment landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hemophilia Market Size by Type & CAGR (2026-2033)

• Market Overview
• Hemophilia A
• Hemophilia B
• Hemophilia C
• Others

Global Hemophilia Market Size by Product & CAGR (2026-2033)

• Market Overview
• Plasma derived coagulation factor concentrates
• Recombinant coagulation factor concentrates
• Desmopressin and antifibrinolytic agents

Global Hemophilia Market Size by Therapy & CAGR (2026-2033)

• Market Overview
• On-demand
• Prophylaxis

Global Hemophilia Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Replacement therapy
• ITI therapy
• Gene Therapy

Global Hemophilia Market Size & CAGR (2026-2033)

• North America (Type, Product, Therapy, Treatment)
  • US
  • Canada
• Europe (Type, Product, Therapy, Treatment)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Product, Therapy, Treatment)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Product, Therapy, Treatment)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Product, Therapy, Treatment)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Chugai Pharmaceutical Co.) (Switzerland/Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (Genzyme Corporation) (France/United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Shire Plc.) (Japan/Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxalta (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioverativ Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kogenate (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations